Glaxo Ditches Raft of R&D Projects to Focus on Top Prospects

GlaxoSmithKline axed more than 30 drug-research projects to focus on four key disease areas, in a push by new Chief Executive Emma Walmsley to sharpen the company’s research-and-development operations.

from WSJ.com: US Business http://ift.tt/2vIxpUX
via IFTTT